D.E. Shaw & Co
HZNP

D.E. Shaw & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

D.E. Shaw & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,718,246
Closed -$546M – 4792
2023
Q3 		$546M Buy
4,718,246
+1,035,866
+28% +$111M 0.57% 11
2023
Q2 		$379M Buy
3,682,380
+1,457,042
+65% +$154M 0.39% 22
2023
Q1 		$243M Buy
2,225,338
+2,145,248
+2,679% +$237M 0.26% 58
2022
Q4 		$9.11M Sell
80,090
-334,088
-81% -$27.7M 0.01% 1519
2022
Q3 		$25.6M Buy
414,178
+390,368
+1,640% +$27.3M 0.03% 710
2022
Q2 		$1.9M Sell
23,810
-246,964
-91% -$23.4M ﹤0.01% 3119
2022
Q1 		$28.5M Buy
270,774
+124,881
+86% +$12.2M 0.03% 807
2021
Q4 		$15.7M Sell
145,893
-109,344
-43% -$11.9M 0.01% 1260
2021
Q3 		$28M Sell
255,237
-169,464
-40% -$17.6M 0.03% 821
2021
Q2 		$39.8M Sell
424,701
-1,192,747
-74% -$110M 0.03% 653
2021
Q1 		$149M Sell
1,617,448
-686,298
-30% -$57.9M 0.14% 144
2020
Q4 		$169M Sell
2,303,746
-735,867
-24% -$54.7M 0.15% 131
2020
Q3 		$236M Buy
3,039,613
+67,181
+2% +$4.62M 0.24% 70
2020
Q2 		$165M Sell
2,972,432
-1,345,321
-31% -$57.6M 0.2% 90
2020
Q1 		$128M Sell
4,317,753
-816,404
-16% -$27.6M 0.2% 100
2019
Q4 		$186M Buy
5,134,157
+24,331
+0.5% +$746K 0.21% 93
2019
Q3 		$139M Buy
5,109,826
+11,897
+0.2% +$308K 0.17% 129
2019
Q2 		$123M Buy
5,097,929
+695,950
+16% +$17.7M 0.15% 146
2019
Q1 		$116M Buy
4,401,979
+1,032,471
+31% +$24.5M 0.15% 151
2018
Q4 		$65.8M Buy
3,369,508
+1,312,142
+64% +$25.7M 0.09% 260
2018
Q3 		$40.3M Buy
2,057,366
+1,277,249
+164% +$24.3M 0.05% 474
2018
Q2 		$12.9M Buy
780,117
+287,032
+58% +$4.38M 0.02% 942
2018
Q1 		$7M Buy
493,085
+139,210
+39% +$2.06M 0.01% 1202
2017
Q4 		$5.17M Buy
353,875
+330,281
+1,400% +$4.64M 0.01% 1464
2017
Q3 		$299K Buy
+23,594
New +$300K ﹤0.01% 3142
2017
Q2 		– Sell
-285,668
Closed -$4.22M – 3634
2017
Q1 		$4.22M Sell
285,668
-838,271
-75% -$13.6M 0.01% 1393
2016
Q4 		$18.2M Buy
1,123,939
+146,483
+15% +$2.66M 0.03% 665
2016
Q3 		$17.7M Buy
977,456
+49,942
+5% +$976K 0.03% 622
2016
Q2 		$15.3M Buy
927,514
+501,697
+118% +$8.12M 0.03% 652
2016
Q1 		$7.06M Sell
425,817
-275,789
-39% -$4.83M 0.01% 1061
2015
Q4 		$15.2M Sell
701,606
-2,395,068
-77% -$46.6M 0.02% 765
2015
Q3 		$61.4M Buy
3,096,674
+1,291,149
+72% +$40.8M 0.09% 272
2015
Q2 		$62.7M Buy
1,805,525
+248,502
+16% +$7.58M 0.09% 254
2015
Q1 		$40.4M Buy
1,557,023
+149,719
+11% +$2.74M 0.06% 368
2014
Q4 		$18.1M Buy
1,407,304
+1,308,771
+1,328% +$16.4M 0.02% 759
2014
Q3 		$1.21M Sell
98,533
-149,727
-60% -$1.74M ﹤0.01% 2652
2014
Q2 		$3.93M Sell
248,260
-548,864
-69% -$7.83M 0.01% 1795
2014
Q1 		$12.1M Buy
797,124
+335,894
+73% +$3.79M 0.02% 934
2013
Q4 		$3.51M Buy
461,230
+441,183
+2,201% +$2.38M ﹤0.01% 1989
2013
Q3 		$68K Buy
+20,047
New +$52.9K ﹤0.01% 4219

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's HZNP Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,718,246 shares — an estimated $546M sold.

D.E. Shaw & Co first reported a position in HZNP in Q3 2013 and held it in 40 quarters. The position peaked at $546M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • D.E. Shaw & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 4,718,246 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $546M.
  • D.E. Shaw & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 40 quarters.
  • D.E. Shaw & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $546M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.